Innate Pharma S.A. (IPHA)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
R&D of Pharmaceutical Products	9.01M	20.12M	61.64M	57.67M	24.70M
R&D of Pharmaceutical Products Growth	-55.25%	-67.36%	6.88%	133.47%	-64.60%
Total	9.01M	20.12M	61.64M	57.67M	24.70M
Total Growth	-55.25%	-67.36%	6.88%	133.47%	-64.60%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
France	9.01M	20.12M	61.64M	57.67M	24.70M
France Growth	-55.25%	-67.36%	6.88%	133.47%	-64.60%
Total	9.01M	20.12M	61.64M	57.67M	24.70M
Total Growth	-55.25%	-67.36%	6.88%	133.47%	-64.60%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 12, 2026

Data Sources Report a data error